ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: To investigate whether this dual BCR-ABL-JAK2 targeting approach may also be therapeutically effective for CML patients who do not respond adequately to treatment with a single TKI, we investigated the molecular and biological effects in primitive CML cells obtained at diagnosis from CML patients (n=7) classified retrospectively following initiation of IM monotherapy, as IM-nonresponders [37, 38].